The FDA has granted a priority review designation to a supplemental new drug application for enzalutamide (Xtandi) for the treatment of men with metastatic hormone-sensitive prostate cancer (mHSPC), according to Astellas Pharma Inc. and Pfizer Inc., the codevelopers of the androgen receptor inhibitor.
There are multiple steps nurses must take to prevent and manage pulmonary toxicities in patients taking immunotherapy.
Two different randomized clinical trials not only validated the value of annual lung cancer screening in patients, but also can open the doors for vital smoking cessation talks.
The Centers for Medicare and Medicaid Services (CMS) announced that it will cover chimeric antigen receptor (CAR) T-cell therapy for Medicare beneficiaries.
Save the date! We invite you to join Oncology Nursing News for an #OncNurseConnect Tweet Chat on Wednesday, August 21.
This is the first approval for this patient population in nearly a decade.
The FDA approved entrectinib for pediatric and adult patients with certain subtypes of solid tumors, including non-small cell lung cancer.
Oncology nurses can make the world of a difference when it comes to patient care, and it is crucial that they work together with other members of the treatment team to ensure the best outcomes, according to Sally Werner, MSHA, BSN, RN, senior vice president, affiliate relations at Cancer Support Community.
Workplace violence for healthcare workers – including nurses – is on the rise. Here’s what nurses need to know about the hot-button topic.
Hair, skin, or nail reactions commonly occur in patients treated with immunotherapy and targeted therapy for cancer.
PARP inhibitors have shown success in breast and ovarian cancer, and now they may be moving into the pancreatic cancer paradigm, too.
Robert M. Wenham, MD discusses evolving strategies in the ovarian cancer space.
The Food and Drug Administration (FDA) approved pexidartinib for the treatment of adults with symptomatic tenosynovial giant cell tumor (TGCT).
About 25% of healthcare-related infections come from catheters, but there are steps nurses can take to mitigate this problem.
Here are the top 5 Oncology Nursing News stories for July 2019.
The FDA approved pembrolizumab to treat certain patients with recurrent, locally advanced or metastatic squamous cell carcinoma of the esophagus.
The FDA has approved darolutamide (Nubeqa) for the treatment of patients with nonmetastatic castration-resistant prostate cancer.
The annual SONO meeting will feature the latest research and pressing topics for oncology nurses.
One expert discusses the arrival of immunotherapy, as well as other exciting advances, for the treatment of patients with small cell lung cancer.
Circulating tumor DNA (ctDNA) monitoring is clinically valid in predicting whether patients with unresectable, metastatic BRAF-mutant melanoma will benefit from dabafenib (Tafinlar) alone or in combination with trametinib (Mekinist).
Several key abstracts presented at the 2019 ASCO Annual Meeting demonstrated practice-changing potential in the prostate cancer field, said Celestia S. Higano, MD, FACP.
Optimizing the methods for preclinical research with an emphasis on patient-derived models, may help speed up the translation of new treatment advances from the laboratory to the clinic, according to a presentation by Charles M. Rudin, MD, PhD, at the 2019 International Lung Cancer Congress.
Many adolescent and young adult cancer survivors struggle in the post-cancer period. Oncology nurses can help ensure that they don’t fall through the cracks.
The Food and Drug Administration granted a priority review for a new drug application for tazemetostat. The drug will be used to treat a rare kind of soft tissue sarcoma that mainly affects young adults.
After months of debate, the Food and Drug Administration announced that they will be taking action to protect women from breast implant-associated anaplastic large cell lymphoma.
Nurse coordinators and other healthcare professionals must work together to provide comprehensive lung cancer screening programs.
The Food and Drug Administration (FDA) approved rituximab-pvvr (Ruxience), a biosimilar to rituximab (Rituxan) for the treatment of blood cancers.
A recent study found that in some parts of the United States, more patients with cancer are treated by nurse practitioners than medical oncologists.
Immunotherapy has drastically changed the treatment landscape for non-small cell lung cancer, but how can practitioners decide who should get frontline chemotherapy, too?
Selective inhibitors for patients with non–small cell lung cancer with rare oncogenic drivers are showing high response rates in clinical trials, explained one expert.
